» Articles » PMID: 37833089

PEER Simplified Lipid Guideline 2023 Update: Prevention and Management of Cardiovascular Disease in Primary Care

Abstract

Objective: To update the 2015 clinical practice guideline and provide a simplified approach to lipid management in the prevention of cardiovascular disease (CVD) for primary care.

Methods: Following the Institute of Medicine's , a multidisciplinary, pan-Canadian guideline panel was formed. This panel was represented by primary care providers, free from conflicts of interest with industry, and included the patient perspective. A separate scientific evidence team performed evidence reviews on statins, ezetimibe, proprotein convertase subtilisin-kexin type 9 inhibitors, fibrates, bile acid sequestrants, niacin, and omega-3 supplements (docosahexaenoic acid with eicosapentaenoic acid [EPA] or EPA ethyl ester alone [icosapent]), as well as on 11 supplemental questions. Recommendations were finalized by the guideline panel through use of the Grading of Recommendations Assessment, Development and Evaluation methodology.

Recommendations: All recommendations are presented in a patient-centred manner designed with the needs of family physicians and other primary care providers in mind. Many recommendations are similar to those published in 2015. Statins remain first-line therapy for both primary and secondary CVD prevention, and the Mediterranean diet and physical activity are recommended to reduce cardiovascular risk (primary and secondary prevention). The guideline panel recommended against using lipoprotein a, apolipoprotein B, or coronary artery calcium levels when assessing cardiovascular risk, and recommended against targeting specific lipid levels. The team also reviewed new evidence pertaining to omega-3 fatty acids (including EPA ethyl ester [icosapent]) and proprotein convertase subtilisin-kexin type 9 inhibitors, and outlined when to engage in informed shared decision making with patients on interventions to lower cardiovascular risk.

Conclusion: These updated evidence-based guidelines provide a simplified approach to lipid management for the prevention and management of CVD. These guidelines were created by and for primary health care professionals and their patients.

Citing Articles

Preventive Lipid-Lowering Therapy and Interactions With Health Care in Patients Who Develop Premature Coronary Artery Disease.

Vikulova D, Lee M, Humphries K, Pinheiro-Muller D, Dawes M, Pimstone S JACC Adv. 2025; 4(1):101316.

PMID: 39811754 PMC: 11730227. DOI: 10.1016/j.jacadv.2024.101316.


Five-Year Trends in Low-Density Lipoprotein Cholesterol Management in a Primary Healthcare Centre in Kaunas.

Urbonas G, Sileikiene L, Valius L, Grigale E, Kaupas V, Juska T Medicina (Kaunas). 2025; 60(12.

PMID: 39768844 PMC: 11678141. DOI: 10.3390/medicina60121963.


Prevention and Management of Cardiovascular Disease in Primary Care: A Comment on the PEER Simplified Lipid Guideline.

Mancini G, Pearson G, Barry A, Couture P, Dayan N, Francis G CJC Open. 2024; 6(10):1189-1198.

PMID: 39525338 PMC: 11544166. DOI: 10.1016/j.cjco.2024.06.006.


Serum Lipid Profile and Electrolytes Reference Intervals for Apparently Healthy Children and Adolescents in Addis Ababa, Ethiopia.

Mohammed O, Kassaw M, Befekadu E, GEgzeabher L, Tolcha Y, Challa F J Clin Lab Anal. 2024; 38(22):e25116.

PMID: 39431864 PMC: 11584307. DOI: 10.1002/jcla.25116.


Rapid recommendations: Updates from 2023 guidelines: part 1.

OToole D Can Fam Physician. 2024; 70(9):555-557.

PMID: 39271218 PMC: 11407600. DOI: 10.46747/cfp.7009555.


References
1.
. Corrigendum to "2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk" [Atherosclerosis 290 (2019) 140-205]. Atherosclerosis. 2019; 294:80-82. DOI: 10.1016/j.atherosclerosis.2019.12.004. View

2.
Muhlestein J, Knowlton K, Le V, Lappe D, May H, Min D . Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial. JACC Cardiovasc Imaging. 2021; 15(5):843-855. DOI: 10.1016/j.jcmg.2021.11.006. View

3.
McCormack J, Holmes D . Your results may vary: the imprecision of medical measurements. BMJ. 2020; 368:m149. DOI: 10.1136/bmj.m149. View

4.
Sud M, Sivaswamy A, Chu A, Austin P, Anderson T, Naimark D . Population-Based Recalibration of the Framingham Risk Score and Pooled Cohort Equations. J Am Coll Cardiol. 2022; 80(14):1330-1342. DOI: 10.1016/j.jacc.2022.07.026. View

5.
Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1046-e1081. DOI: 10.1161/CIR.0000000000000624. View